A Fiveyear Comparison of the Renal Protective Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with NonDiabeticNephropathy
- 1 January 2006
- journal article
- research article
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 45 (4), 193-198
- https://doi.org/10.2169/internalmedicine.45.1515
Abstract
Evidence suggests that the effectiveness of angiotensin-converting enzyme (ACE) inhibition diminishes with time, resulting in increasing angiotensin II levels, the action of which can be inhibited by the addition of an angiotensin receptor blocker (ARB). In the present study, the renal protective effects of ACE inhibitors and ARBs were compared over a five-year period in a prospective, randomized, open-blind study in 68 nondiabetic Japanese patients with elevated serum creatinine levels. Japanese patients with renal insufficiency were randomly assigned to receive either an ACE inhibitor (benazepril 1.25 to 5 mg daily or trandolapril 0.5 to 4 mg daily) or ARB (candesartan 2 to 8 mg daily or losartan 25 to 100 mg daily) at the Kidney Disease Center at Saitama Medical School Hospital. The primary study endpoint was a change in glomerular filtration rate (GFR) between the baseline value and the last available value obtained during the five-year treatment period, as estimated by the Cockcraft-Gault equation. Secondary endpoints included the annual changes in GFR, serum creatinine level, urinary protein excretion, and blood pressure, as well as the rate of development of endstage renal disease. There were no significant differences in the primary endpoint between the two groups. However, after 4 years, the decline in GFR in patients treated with ARBs was significantly greater than that seen in patients treated with an ACE inhibitor (p<0.05). Furthermore, the rate of introduction of dialysis therapy was also significantly greater in the ARB-treated patients (52.7% in ACE inhibitor and 81.2% in ARB group at year 5. p<0.01). While our data suggested that ARB, like ACE, treatment might slow the progression of renal dysfunction, it also pointed to the necessity to be alerted to the progression to endstage renal disease with longterm medication.Keywords
This publication has 21 references indexed in Scilit:
- Cardiovascular and Renal Regulation by the Angiotensin Type 2 ReceptorHypertension, 2005
- Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2004
- Cardiovascular disease and chronic kidney disease: Insights and an updateAmerican Heart Journal, 2004
- OverviewJournal of the American Society of Nephrology, 2004
- Angiotensin Type 1 Receptor Blockers in Chronic Kidney DiseasePublished by S. Karger AG ,2004
- Safety of the combination of valsartan and benazepril in patients with chronic renal diseaseJournal Of Hypertension, 2000
- Treatment of Hypertension in Chronic Renal Insufficiency.Internal Medicine, 2000
- Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal InsufficiencyNew England Journal of Medicine, 1996
- Reactive Hyperreninemia Is a Major Determinant of Plasma Angiotensin II During ACE InhibitionJournal of Cardiovascular Pharmacology, 1990
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976